Skip to main content

Salvage therapy in Hodgkin's lymphoma.

Publication ,  Journal Article
Byrne, BJ; Gockerman, JP
Published in: Oncologist
February 2007

Hodgkin's disease is a rare malignancy that affects approximately 7,500 patients per year in the U.S., leading to an estimated 1,400 deaths. The relapse rate for this disease varies from around 5% for early-stage disease to 35% for patients with advanced disease. Patients who relapse after chemotherapy have about a 20% cure rate with conventional salvage chemotherapy. Two randomized phase III studies have shown an improved failure-free survival rate with high-dose chemotherapy and autologous stem cell support compared with conventional chemotherapy in relapsed patients. They failed to show any improvement in overall survival. For patients who experience failure with autologous transplant, the options of single-agent chemotherapy with gemcitabine, vinblastine, or vinorelbine can be used for palliation. Standard myeloablative allogeneic bone marrow transplant has a high mortality rate in this population. Allogeneic transplant regimens with reduced intensity are currently being studied in clinical trials. Further studies on the use of monoclonal antibodies and radiolabeled antibodies need to be conducted to define their role in the treatment of Hodgkin's disease.

Duke Scholars

Published In

Oncologist

DOI

ISSN

1083-7159

Publication Date

February 2007

Volume

12

Issue

2

Start / End Page

156 / 167

Location

England

Related Subject Headings

  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Humans
  • Hodgkin Disease
  • Hematopoietic Stem Cell Transplantation
  • Combined Modality Therapy
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Byrne, B. J., & Gockerman, J. P. (2007). Salvage therapy in Hodgkin's lymphoma. Oncologist, 12(2), 156–167. https://doi.org/10.1634/theoncologist.12-2-156
Byrne, Brian J., and Jon P. Gockerman. “Salvage therapy in Hodgkin's lymphoma.Oncologist 12, no. 2 (February 2007): 156–67. https://doi.org/10.1634/theoncologist.12-2-156.
Byrne BJ, Gockerman JP. Salvage therapy in Hodgkin's lymphoma. Oncologist. 2007 Feb;12(2):156–67.
Byrne, Brian J., and Jon P. Gockerman. “Salvage therapy in Hodgkin's lymphoma.Oncologist, vol. 12, no. 2, Feb. 2007, pp. 156–67. Pubmed, doi:10.1634/theoncologist.12-2-156.
Byrne BJ, Gockerman JP. Salvage therapy in Hodgkin's lymphoma. Oncologist. 2007 Feb;12(2):156–167.

Published In

Oncologist

DOI

ISSN

1083-7159

Publication Date

February 2007

Volume

12

Issue

2

Start / End Page

156 / 167

Location

England

Related Subject Headings

  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Humans
  • Hodgkin Disease
  • Hematopoietic Stem Cell Transplantation
  • Combined Modality Therapy
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis